Contact this trialFirst, we need to learn more about you.
Dopamine Receptor 1 Partial Agonist
Dopamine Receptor Agonist for Schizophrenia
Recruiting0 awardsPhase 1 & 2
Stony Brook, New York
This trial tests CVL-562, a new medicine that helps activate brain receptors related to dopamine, in patients with early episode schizophrenia who have memory problems. The goal is to see if it can improve their thinking and memory by enhancing brain activity.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.